Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group

C. G. Moertel, S. Frytak, R. G. Hahn, M. J. O'Connell, R. J. Reitemeier, J. Rubin, A. J. Schutt, L. H. Weiland, D. S. Childs, M. A. Holbrook, P. T. Lavin, E. Livstone, H. Spiro, A. Knowlton, M. Kalser, Jamie S Barkin, H. Lessner, R. Mann-Kaplan, K. Ramming, H. O. DouglasP. Thomas, H. Nave, J. Bateman, J. Lokich, J. Brooks, J. Chaffey, J. M. Corson, N. Zamcheck, J. W. Novak

Research output: Contribution to journalArticle

899 Citations (Scopus)

Abstract

194 eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 5 1/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. 40% of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of 10 months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.

Original languageEnglish
Pages (from-to)1705-1710
Number of pages6
JournalCancer
Volume48
Issue number8
DOIs
StatePublished - Dec 14 1981

Fingerprint

Fluorouracil
Radiation
Survival
Neoplasms
Therapeutics
Pancreas
Adenocarcinoma
Radiotherapy
Pancreatic Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Therapy of locally unresectable pancreatic carcinoma : A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group. / Moertel, C. G.; Frytak, S.; Hahn, R. G.; O'Connell, M. J.; Reitemeier, R. J.; Rubin, J.; Schutt, A. J.; Weiland, L. H.; Childs, D. S.; Holbrook, M. A.; Lavin, P. T.; Livstone, E.; Spiro, H.; Knowlton, A.; Kalser, M.; Barkin, Jamie S; Lessner, H.; Mann-Kaplan, R.; Ramming, K.; Douglas, H. O.; Thomas, P.; Nave, H.; Bateman, J.; Lokich, J.; Brooks, J.; Chaffey, J.; Corson, J. M.; Zamcheck, N.; Novak, J. W.

In: Cancer, Vol. 48, No. 8, 14.12.1981, p. 1705-1710.

Research output: Contribution to journalArticle

Moertel, CG, Frytak, S, Hahn, RG, O'Connell, MJ, Reitemeier, RJ, Rubin, J, Schutt, AJ, Weiland, LH, Childs, DS, Holbrook, MA, Lavin, PT, Livstone, E, Spiro, H, Knowlton, A, Kalser, M, Barkin, JS, Lessner, H, Mann-Kaplan, R, Ramming, K, Douglas, HO, Thomas, P, Nave, H, Bateman, J, Lokich, J, Brooks, J, Chaffey, J, Corson, JM, Zamcheck, N & Novak, JW 1981, 'Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group', Cancer, vol. 48, no. 8, pp. 1705-1710. https://doi.org/10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4
Moertel, C. G. ; Frytak, S. ; Hahn, R. G. ; O'Connell, M. J. ; Reitemeier, R. J. ; Rubin, J. ; Schutt, A. J. ; Weiland, L. H. ; Childs, D. S. ; Holbrook, M. A. ; Lavin, P. T. ; Livstone, E. ; Spiro, H. ; Knowlton, A. ; Kalser, M. ; Barkin, Jamie S ; Lessner, H. ; Mann-Kaplan, R. ; Ramming, K. ; Douglas, H. O. ; Thomas, P. ; Nave, H. ; Bateman, J. ; Lokich, J. ; Brooks, J. ; Chaffey, J. ; Corson, J. M. ; Zamcheck, N. ; Novak, J. W. / Therapy of locally unresectable pancreatic carcinoma : A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group. In: Cancer. 1981 ; Vol. 48, No. 8. pp. 1705-1710.
@article{7d5bf67c074d41229df997a6d6ece5c4,
title = "Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group",
abstract = "194 eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 5 1/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. 40{\%} of patients treated with the combined regimens were still living at one year compared with 10{\%} of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of 10 months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.",
author = "Moertel, {C. G.} and S. Frytak and Hahn, {R. G.} and O'Connell, {M. J.} and Reitemeier, {R. J.} and J. Rubin and Schutt, {A. J.} and Weiland, {L. H.} and Childs, {D. S.} and Holbrook, {M. A.} and Lavin, {P. T.} and E. Livstone and H. Spiro and A. Knowlton and M. Kalser and Barkin, {Jamie S} and H. Lessner and R. Mann-Kaplan and K. Ramming and Douglas, {H. O.} and P. Thomas and H. Nave and J. Bateman and J. Lokich and J. Brooks and J. Chaffey and Corson, {J. M.} and N. Zamcheck and Novak, {J. W.}",
year = "1981",
month = "12",
day = "14",
doi = "10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4",
language = "English",
volume = "48",
pages = "1705--1710",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Therapy of locally unresectable pancreatic carcinoma

T2 - A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group

AU - Moertel, C. G.

AU - Frytak, S.

AU - Hahn, R. G.

AU - O'Connell, M. J.

AU - Reitemeier, R. J.

AU - Rubin, J.

AU - Schutt, A. J.

AU - Weiland, L. H.

AU - Childs, D. S.

AU - Holbrook, M. A.

AU - Lavin, P. T.

AU - Livstone, E.

AU - Spiro, H.

AU - Knowlton, A.

AU - Kalser, M.

AU - Barkin, Jamie S

AU - Lessner, H.

AU - Mann-Kaplan, R.

AU - Ramming, K.

AU - Douglas, H. O.

AU - Thomas, P.

AU - Nave, H.

AU - Bateman, J.

AU - Lokich, J.

AU - Brooks, J.

AU - Chaffey, J.

AU - Corson, J. M.

AU - Zamcheck, N.

AU - Novak, J. W.

PY - 1981/12/14

Y1 - 1981/12/14

N2 - 194 eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 5 1/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. 40% of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of 10 months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.

AB - 194 eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 5 1/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. 40% of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of 10 months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.

UR - http://www.scopus.com/inward/record.url?scp=0019410935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019410935&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4

DO - 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4

M3 - Article

C2 - 7284971

AN - SCOPUS:0019410935

VL - 48

SP - 1705

EP - 1710

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -